Oramed Pharmaceuticals Inc. ORMP
Set alert
4.02 USD +0.02 +0.50%
As of Nov 3, 10:06 AM ET
4.02 Day range 4.05
2.09 52-week range 5.47
- YTD
- +41.05%
- 1 year
- +70.34%
- Open
- 4.02
- Prev close
- 4.00
- Mkt cap
- 165.34M
- Vol
- 8.38K
- Avg vol
- 178.58K
- EPS
- 4.13
- P/E
- 0.98
- Div yield
- 5.91%
More statistics
- Low
- 4.02
- High
- 4.05
- Forward P/E
- -29.75
- Beta
- 1.77
- Short ratio
- 2.60
- Inst. own
- 17.52%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 2.38
- 200-d avg
- 2.43
- 1y target
- 3.25
MAX chart
Events in this range
- Mar 6, 2024Earnings: -0.08; estimate -0.12; surprise 33.33%
- Nov 7, 2024Earnings: -0.48; estimate 0.01; surprise -4900%
Signals (75)
| Name | Date | Ago |
|---|---|---|
| SMA: Bullish | Nov 1, 2025 | 1 year ago |
| SMA: Bearish | Oct 1, 2025 | 1 year ago |
| SMA: Bullish | Sep 1, 2025 | 1 year ago |
| SMA: Bullish | Sep 1, 2025 | 1 year ago |
| SMA: Bearish | Jun 1, 2025 | 1 year ago |
| SMA: Bullish | May 1, 2025 | 1 year ago |
| SMA: Bearish | Aug 1, 2024 | 2 years ago |
| SMA: Bullish | Jun 1, 2024 | 2 years ago |
| SMA: Bearish | Apr 1, 2024 | 2 years ago |
| MACD: Buy Signal | Feb 1, 2024 | 2 years ago |
| SMA: Bullish | Jan 1, 2024 | 2 years ago |
| SMA: Bearish | Jan 1, 2023 | 3 years ago |
| SMA: Bearish | Jan 1, 2023 | 3 years ago |
| SMA: Bullish | Dec 1, 2022 | 3 years ago |
| SMA: Bullish | Nov 1, 2022 | 4 years ago |
| SMA: Bearish | Apr 1, 2022 | 4 years ago |
| MACD: Sell Signal | Feb 1, 2022 | 4 years ago |
| SMA: Bearish | Dec 1, 2021 | 4 years ago |
| RSI: Overbought | Feb 1, 2021 | 5 years ago |
| SMA: Bullish | Nov 1, 2020 | 6 years ago |
Newest 20 of 75.
Analyst view
Consensus: none
Price target (mean) 3.25
Ratings (0m) 1 0 buy · 1 hold · 0 sell
- Strong buy0
- Buy0
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 1
- 1 month ago 1
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.07 | -0.07 – -0.07 | 0.33 | -121.2% | 0 | 0.0% | 1 |
| Next quarter | -0.05 | -0.05 – -0.05 | 0.00 | 0.0% | 500.00K | 0.0% | 1 |
| Current year | 0.17 | 0.17 – 0.17 | 0.14 | +21.4% | 0 | -100.0% | 1 |
| Next year | -0.26 | -0.26 – -0.26 | 0.17 | -252.9% | 1.00M | 0.0% | 1 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Sep 9, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| May 20, 2024 | HC Wainwright & Co. | Reiterated | — | Neutral |
| May 17, 2023 | Canaccord Genuity | Maintained | Hold | Hold |
| Jan 17, 2023 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| Jan 12, 2023 | Canaccord Genuity | Downgrade | Buy | Hold |
| May 16, 2022 | Aegis Capital | Maintained | — | Buy |
| Feb 18, 2022 | Cantor Fitzgerald | Initiated | — | Overweight |
| Nov 30, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 29, 2021 | HC Wainwright & Co. | Maintained | — | Buy |
| Nov 2, 2021 | Aegis Capital | Maintained | — | Buy |
| Jul 29, 2021 | Canaccord Genuity | Maintained | — | Buy |
| Jun 8, 2021 | Aegis Capital | Maintained | — | Buy |
| Apr 20, 2021 | Canaccord Genuity | Initiated | — | Buy |
| Feb 9, 2021 | National Securities Corporation | Initiated | — | Buy |
| Jan 27, 2021 | Aegis Capital | Maintained | — | Buy |
| Jul 13, 2020 | HC Wainwright & Co. | Reiterated | — | Buy |
| Jun 22, 2020 | HC Wainwright & Co. | Maintained | — | Buy |
| Sep 11, 2019 | Ladenburg Thalmann | Initiated | — | Buy |
| Nov 19, 2015 | FBR Capital | Initiated | — | Outperform |
| Oct 1, 2015 | HC Wainwright & Co. | Initiated | — | Buy |
| Dec 4, 2013 | Aegis Capital | Initiated | — | Buy |